TARGET ARTICLE

Check for updates

Racial Justice Requires Ending the War on Drugs

Brian D. Earp^a (b), Jonathan Lewis^b (b), and Carl L. Hart^c, with Bioethicists and Allied Professionals for Drug Policy Reform^d

^aYale University; ^bDublin University; ^cColumbia University; ^dSee Appendix for full author details

ABSTRACT

Historically, laws and policies to criminalize drug use or possession were rooted in explicit racism, and they continue to wreak havoc on certain racialized communities. We are a group of bioethicists, drug experts, legal scholars, criminal justice researchers, sociologists, psychologists, and other allied professionals who have come together in support of a policy proposal that is evidence-based and ethically recommended. We call for the immediate decriminalization of all so-called recreational drugs and, ultimately, for their timely and appropriate legal regulation. We also call for criminal convictions for nonviolent offenses pertaining to the use or possession of small quantities of such drugs to be expunged, and for those currently serving time for these offenses to be released. In effect, we call for an end to the "war on drugs."

KEYWORDS

race and culture/ethnicity; health policy; regulatory issues

A series of prominent killings of unarmed Black people by police in spring 2020 has renewed calls to address systemic racism in the United States and around the world. Among those killed was Breonna Taylor, whose home was wrongfully entered by officers without warning as part of a drug-related search. As we will detail, Black people in the United States are disproportionately targeted, arrested, and incarcerated for crimes related to non-medical drug use, and this is one area where social reform is urgently needed. We are a group of bioethicists, drug experts, legal scholars, criminal justice researchers, sociologists, psychologists, and other allied professionals (see Appendix for details) who have come together in support of a policy proposal that is evidence-based and ethically recommended. We call for the immediate decriminalization of all psychoactive substances currently deemed illicit for personal use or possession,¹ and, ultimately, for their full legalization and careful regulation. In effect, we call for an end to the "war on drugs."

In principle, the "war on drugs" aims to protect people from harm and promote public health. In

practice, it has worsened many aspects of public health while inordinately harming certain racialized communities (Mauer and King 2007). In addition, the "war on drugs" has fostered a condescending moral-ism that conflates drug use with violence or bad char-acter and casts drug users-especially Black and Hispanic drug users-as criminals-in-waiting who deserve to be punished (Mallea 2014). Indeed, the very language of a "war" can work to reinforce "a set of beliefs and values that stress the use of force and domination as appropriate means to solve problems and gain political power" (Kraska and Kappeler 1997). In contrast to this approach, we argue for ending the drug war and investing in the most heavily affected communities. If managed carefully, this shift in policy will not only improve public health, reduce crime and recidivism, lower unemployment and poverty rates, and save governments large sums of money (which could be better spent; see Box 1); it will strike a neces-sary blow against racial injustice.

The context here is instructive. Historically, drug laws and enforcement have reflected and perpetuated explicit racism, including early legislation against

CONTACT Brian D. Earp Shrian.earp@yale.edu Philosophy and Psychology, Yale University, New Haven, CT, USA.

¹By "decriminalization" we mean that all relevant jurisdictions should adopt *de jure* decriminalization so that criminal penalties for the personal possession and use of small amounts of currently illicit drugs are removed by an act of legislation or judicial decision. This is in contrast to merely *de facto* decriminalization, whereby the suspension of criminal penalties depends on local, contingent administrative or law enforcement practices, such as the non-enforcement of the relevant laws and/or referral of offenders to treatment or education programs (Single, Christie, and Ali 2000; Hughes et al. 2016). Thus, although we will argue that individuals struggling with substance-related disorders or other drug-related difficulties should be offered treatment and education, such supportive efforts should be handled through social care institutions that are not tied to the criminal justice system. © 2020 Taylor & Francis Group, LLC

153

Box 1. Saving money and reinvesting in communities.

Drug prohibition harms communities because it is a poor use of limited public resources. For communities that lack sufficient public investment in education, health care, social housing, or infrastructure, drug prohibition diverts public resources away from more socially pressing and worthwhile causes. In the U.S., it is estimated that state and local annual expenditure on drug prohibition amounts to \$29 billion, with an additional \$18 billion of federal spending (Miron 2018). Meanwhile, drug legalization could yield \$58 billion in federal, state, and local tax revenues, with up to \$106.7 billion in overall annual budgetary gains for federal, state, and local governments (Miron 2018).

In states that have legalized cannabis, education and public health programs, including substance use disorder treatment and drug use prevention programs, have been the biggest beneficiaries of cannabis tax revenues (DPA 2018). For instance, in Colorado, the state distributed \$230 million to its Department of Education between 2015 and 2017 (Colorado Department of Education 2018). In 2019, Washington State collected a total of \$390.3 million from cannabis excise and sales tax, with \$188.3 million distributed to health care programs and \$9.5 million to substance use disorder, education, and prevention initiatives (Washington State Liquor and Cannabis Board 2019). And as a part of California's Adult Use of Marijuana Act (Proposition 64), the California Community Reinvestment Grants ("CalCRG") program has allocated \$28.5 million of the revenues from cannabis legalization to support restorative justice projects (with an additional \$30 million planned for 2021, \$40 million for 2022 and \$50 million for 2023), focusing on job placements, mental health treatment, substance use disorder treatment, legal services to address barriers to societal reentry, and access to medical care (California Community Reinvestment Grants Program 2019).

These states have shown that they are able and willing not only to allocate large percentages of the saved funds toward social goods including schools, health care, and infrastructure (DPA 2018), but also to invest in community-building projects for communities that have been disproportionately affected by the "war on drugs," mass supervision, and mass incarceration. But we need to be clear. To fully rebuild those communities that struggle with the greatest concentration of substance use disorders, and which suffer from the cumulative, collateral effects of unjust drug enforcement will require public and charitable expenditures that significantly exceed the potential savings from ending prohibition in any given municipality or state.² Responsibly reinvesting these savings is a minimum first step, not a final answer.

Chinese "opium dens" and Mexican "reefer madness" (Musto 1999; Manderson 1999; Vagins and McCurdy 2006; Provine 2007; Fellner 2009; Campos 2012; Lopez 2014; Luna 2016; Netherland and Hansen 2016; Rosino and Hughey 2018). As we will discuss, the harmful effects of prohibition continue to be especially burdensome for certain racialized groups. Black and Hispanic men, in particular, are subject to heightened scrutiny in relation to suspected drug-related activities, for example, during "investigatory" traffic stops (Weitzer and Brunson 2015; Epp et al. 2017). They are more often met with police use of force, controlling for potentially confounding variables (see Fryer Jr. 2019). They are more likely to face arrest, prosecution, conviction, and incarceration (Mauer and King 2007; Fellner 2009; Mitchell and Caudy 2015; Koch, Lee, and Lee 2016; Nellis 2016; Omori 2019). Moreover, when convicted, they face harsher criminal penalties (Turner and Dawkar 2014; TSP 2018; Lynch 2019).

145These discriminatory practices exacerbate vulner-146abilities within affected communities, including those147mired in structural disadvantages tracing back to slav-148ery and Jim Crow—with persisting inequities that are149still widely underestimated (Small 2001; Nunn 2002;150Clear 2007; Alexander 2010; Del Toro et al. 2019;151Onyeador et al. 2020). It has become evident that152piecemeal reforms are not enough to address these

 154
 ²Potential federal enforcement savings are unlikely to result in a significant reduction in the size or budgets of the many agencies involved that are not exclusively focused on drug enforcement, and specialized drug enforcement agency funding is likely to be reprogrammed to regulatory enforcement. problems. Rather, what is needed is a paradigm shift in how we think about drugs in society. As we will argue, even if racial discrimination in drug arrests, prosecutions, and sentencing could somehow be eliminated, drug prohibition itself would remain unjust and harmful on balance (Huemer 2007; Fellner 2009).

Our proposal to decriminalize and subsequently legalize non-medical drug use applies especially to cannabis, as the benefits and risks of this drug and associated policy options have been the most exhaustively researched. Cannabis is, on the whole, much less harmful to users and others than alcohol, tobacco, and a range of prescription medications that are not prohibited despite the greater potential for dependence and abuse (Nutt, King, and Phillips 2010; Anomaly 2013). But changing the policy on cannabis does not go far enough. In our view, the deep-seated racial injustices associated with current drug laws and their biased enforcement, the harms associated with illegal drug markets that thrive under prohibition, and the violence both within and between communities that such markets engender, call for a more comprehensive approach. Accordingly, we are in favor of the ultimate legalization and careful regulation of MDMA (ecstasy), psychedelic drugs such as LSD and psilocybin, heroin and other opioids, methamphetamine, and powder and crack cocaine-that is, all drugs used for nonmedical purposes that are currently deemed illicit (for related discussions, see e.g., Abbott et al. 2020; Hoss 2019; Marlan 2020).

The personal use and possession of small quantities of these substances, we argue, should be entirely 158 159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

excluded from the purview of criminal law (see footnote 1 for details). Policymakers should pursue this first step-decriminalization-without delay. Although this step alone would, at least in principle, mitigate some of the harms and injustices we have mentioned, the shift away from prohibition would of course need to be accompanied by supportive policies and initiatives to minimize the risks and potential negative externalities that might be associated with such a transition. In particular, while the groundwork for a fully legalized and regulated system is being developed, a combination of decriminalization and harm reduction akin to the Portugal model (see below) is strongly advised.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

The bottom line, however, is that if and when problems with substance use or misuse arise, these should be approached through healthcare programs and social support, not prison time. Moreover, once the groundwork for legalization has been laid, the production, storage, handling, distribution, sale, and supply of drugs currently deemed to be illicit should be legally regulated like other drugs in the U.S. and the Anglosphere in general, such as alcohol, nicotine, and prescription medications.³

As a part of this process, policymakers should directly involve current and former drug users and their social networks in the revision of relevant policy, while implementing community-building programs based on coherent, long-term strategies that meet the needs of those affected (for details and further discussion, see Zigon 2019). We suggest that policymakers also develop racial and ethnic impact statements for any new regulations or changes to existing laws (DPA 2015).

Two final points of clarification. First, it is not our aim to argue either for or against the prudence or permissibility of personal use of drugs for non-medical purposes. Thus, in advocating for the proposed policy changes, we are not making any specific normative commitment as to whether individuals should or should not use any of the aforementioned drugs. More importantly, we do not suggest that all currently illicit drugs should be readily available to any potential consumer: the precise modes of access, and barriers to accessibility, must depend on the drug and its particular profile of benefits and risks as it would

264 realistically be used under different conditions.⁴ Accordingly, it is possible that some drugs should be 265 266 heavily regulated, with their sale or administration 267 requiring, for example, a special license, and/or some 268 individuals who are at an especially high risk of harm 269 being dissuaded by appropriate means (e.g., a person 270with severe psychosis seeking access to a high dose of 271 psilocybin; see Smith and Sisti 2020). The question of 272 how to devise and implement such regulatory policies 273 in order to minimize harms and achieve successful 274compliance is beyond the scope of this paper. 275 Nevertheless, we maintain that many, if not most, 276 of the negative outcomes that are associated with 277 so-called recreational drug use and dissemination in 278 society are either produced or made worse through 279 prohibition (Ostrowski 1991; Barnett 2009; Hart 2013; 280 Todd 2018; Hart 2020). 281

Second, our paper should not be read as a general 282 defense of the rights of adults to access, possess, and/ 283 or use drugs currently deemed illicit nor is it an 284 attempt to argue for the constitutional protection of 285 such rights enforced by the judiciary. Although we are 286 not, in principle, opposed to a rights-based approach 287 (for example, see Flanigan 2017), we intend our pro-288 posals to be considered within the domain of demo-289 cratic politics. This is, therefore, a call for citizens to 290 lobby their elective representatives, and for policy-291 makers at state and federal levels to act by drawing up 292 and passing appropriate legislation, and/or ensuring 293 that these ideas are put on the ballot.⁵ 294

DRUG PROHIBITION HARMS USERS

The standard case for drug prohibition is that it protects people from using certain drugs, which are thought to be harmful and inherently addictive. However, the "war on drugs" is based on a misunderstanding of the science of addiction (for example, it discounts contextual factors contributing to harmful

295

296

297

298

299

300

301

302

303

304 ⁴Obviously, further painstaking scientific research into such benefits and 305 risks will be necessary to inform relevant policies. Also note: the case of 306 heroin-assisted treatment in the Netherlands offers an example of the ways in which different regulatory standards can be operationalized for 307 different substances (Blanken et al. 2010). 308 ⁵Recent events have proved encouraging. While our article was under review in November of 2020, ballot measures were passed in the U.S. 309 state of Oregon simultaneously decriminalizing the possession of all 310 currently illicit drugs for personal use, legalizing the therapeutic use of 311 psilocybin, and expanding access to evidence-informed drug treatment, peer support, housing, and harm reduction services. During the same 312 time period, voters in Arizona, Montana, New Jersey, and South Dakota 313 opted to legalize cannabis use, bringing the total to 15 U.S. states plus the District of Columbia that have legalized cannabis. Non-medical 314 cannabis use is decriminalized in a further 15 U.S. states, as are all so-315 called recreational drugs in Portugal as of 2001 (Greenwald 2009; Hughes and Stevens 2010; Kreit 2010; Silvestri 2015). 316

³Criminal penalties could still apply to certain activities, of course, such as the unlawful sale or manufacture of certain drugs, even under a legalized system. However, such a system would ensure that individuals are not targeted with offenses relating to personal possession and use.

317 drug use; see more generally Hart 2020; Pickard 318 2020), and it undermines the wellbeing of people who 319 use drugs (Barnett 2009; Room and Reuter 2012; 320 Csete et al. 2016), especially low-income racial and 321 ethnic minorities (Clifford 1992; Provine 2007). 322 Prohibition has not met its explicit aim of substan-323 tially lowering the overall rate of drug use, partly 324 because severity-based deterrence, enforced by crimin-325 alization of drug possession and use, has historically 326 been counterproductive (MacCoun 1993). Indeed, 327 there has been an increase in global consumption of 328 illicit substances over the last half century (Hall 329 2018).⁶ Drug prohibition, like alcohol prohibition, is 330 criminogenic and can therefore be harmful to both 331 users and non-users; it can motivate users to commit 332 burglaries and robberies in order to purchase drugs; it 333 contributes to systemic violence; it is associated with 334 corruption in the criminal justice system; it diverts 335 law enforcement efforts away from solving predatory 336 crimes and arresting their perpetrators; and it can 337 contribute to a cycle of ongoing criminal behavior for 338 those who hold criminal records for trivial drug-339 related offenses (Duke 2009). 340

When combined with criminalization, prohibition 341 harms users by exposing them to criminal sanction, 342 making them more vulnerable to arrest and incarcer-343 ation-which itself poses health risks, including lower 344 life expectancy and inadequate access to treatment for 345 substance use disorders (Mauer and King 2007; 346 Barnett 2009; Csete et al. 2016). In addition, prison 347 conditions as normally found in the U.S. isolate peo-348 ple from their friends and family, deprive them of 349 education and employment opportunities, exacerbate 350 mental health problems, and may make people more 351 prone to aggression (Petteruti and Walsh 2008; 352 Raphael and Stoll 2009; Harding 2019). These experi-353 ences can generate lifelong personal, economic, and 354 social obstacles (including for those who only experi-355 ence community supervision), such as barriers to 356 housing, employment, and welfare, as well as the 357 denial of voting rights (Western 2002; Clear 2007; 358 Petersilia 2009; Western and Pettit 2010; Natapoff 359

2020). Even the knowledge that one is subject to surveillance and the heightened risk of incarceration can be highly distressing (Miller and Stuart 2017; Del Toro et al. 2019).

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

From a wider public health perspective, prohibition undermines programs to reduce disease transmission within drug-using communities (Bertram et al. 1996; Rhodes and Hedrich 2010; WHO 2014; Csete et al. 2016; UN 2019), perpetuates unhelpful stigma surrounding drug use (Ahern, Stuber, and Galea 2007; Csete et al. 2016; Buchman, Leece, and Orkin 2017; UN 2019), and discourages users from seeking medical and non-medical help and support when needed (Bertram et al. 1996; Ahern, Stuber, and Galea 2007; Csete et al. 2016; Buchman, Leece, and Orkin 2017; UN 2019). As such, drug prohibition imposes a multitude of health-related costs. As we will discuss, it leads to unsafe drug use and inadequate knowledge of the real effects of drugs; it provides barriers to treatment for substance-related disorders; it diverts funds away from health organizations; it can threaten or block access to the therapeutic benefits of certain drugs; and it precludes the existence of "safe supply" programs and health and safety regulations relating to presently illegal drugs.

DRUG PROHIBITION HARMS COMMUNITIES AND FEEDS SYSTEMIC RACISM

As we noted, drug prohibition and criminalization reflect and perpetuate racial injustice in many contexts (Musto 1999; Vagins and McCurdy 2006; Provine 2007; Fellner 2009; Campos 2012; Lopez 2014; Csete et al. 2016; Luna 2016; Netherland and Hansen 2016; Rosino and Hughey 2018). These policies have been directly linked to police militarization and brutality (ACLU 2014) and are among the important contributing factors to mass incarceration and mass supervision, especially of Black and Hispanic men (Sterling 2004; Alexander 2010; Pfaff 2017).

One of the most significant problems with prohibition is that it leads to illicit markets: specifically, unregulated markets that result in the production of drugs of unknown and inconsistent purity, and, in many cases, dangerous bulking agents and toxic additives, thus increasing rather than reducing the potential for harm (Barnett 2009; Csete et al. 2016; Veit 2018). It has also contributed to the production of novel psychoactive substances in an attempt to circumvent existing laws. Accordingly, some jurisdictions have responded with "catch all" laws against all psychoactive substances, including those not currently

³⁶⁰ ⁶Note: even if decriminalization did lead to an increase in the rate of 361 non-medical drug use among certain subgroups, it would still be an effective policy if it reduced the overall harm to drug users and to society 362 at large (e.g., by reducing violence associated with illegal drug markets). 363 In this context, it should be noted that U.S. government drug policy has 364 primarily sought to undermine the capacity of drug suppliers to meet, grow, and benefit financially from drug demand, so as to drive up drug 365 prices and lower drug purity. These measures were intended to make it 366 prohibitive to start using drugs while incentivizing treatment efforts by making it harder for users to sustain their habits. However, drug 367 prohibition and enforcement have not achieved these ends. Rather, drug 368 prices have generally fallen or remained stable, drug potency has increased, and drug use has steadily risen (Sterling 2006). 369

prohibited, but these laws have a number of problems (see, for example, Thorne Harbour Health 2017).

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

Prohibition also fails to deal with the background conditions, such as deep-rooted economic deprivation, that sustain illegal industries (Thoumi 2003), and the associated exploitation of structurally vulnerable indicriminal gangs and viduals by drug cartels (Wainwright 2016). Prohibition thus expands opportunities for crimes against drug users (Barnett 2009) and sets the stage for violence within and between criminal organizations, as well as violence against state officials and innocent parties (Reuter 2009; Thoumi 2010; Csete et al. 2016).⁷ Furthermore, reductions in community safety and cohesion are exacerbated by increased exposure to state-backed violence and law enforcement, including dangerous raids by SWAT teams and other forms of policing that disproportionately target Black neighborhoods (Beckett, Nyrop, and Pfingst 2006; ACLU 2014; Ghandnoosh 2015).

In the U.S., overall rates of illicit drug use and opioid misuse among Black people are very similar to those among White people (Figure 1). However, Black people are more likely to be arrested, prosecuted, convicted, and incarcerated-with longer sentences-for drug offenses (Vagins and McCurdy 2006; Mauer and King 2007; Fellner 2009; Turner and Dawkar 2014; Mitchell and Caudy 2015; Csete et al. 2016; Koch, Lee, and Lee 2016; Nellis 2016; Lynch 2019; Omori 2019). Notably, sentencing disparities persist even after accounting for baseline differences in criminal history and crime severity (see, e.g., Steffensmeier and Demuth 2000, 2001; Spohn 2000). Moreover, the possession or distribution of drugs that are perceived to be more commonly used by Black people (e.g., crack cocaine) than by Whites people (e.g., powder cocaine) have been associated with harsher sentences,8 despite approximately similar harm/benefit profiles and chemical constitutions (Vagins and McCurdy 2006; Lynch and Omori 2018).

When we take into account the harms of incarceration to individuals that have already been mentioned, initial race disparities in arrests, convictions, and sentencing can lead to and maintain long-term

476 vulnerabilities and widening socio-economic dispar-477 ities (Chin 2002; Clear 2007; Alexander 2010). In 478 turn, differences in socio-economic status can contrib-479 ute to disparities in the effectiveness of substance 480 abuse treatment programs. Specifically, Black and 481 Hispanic people, who make up approximately 40 per-482 cent of the admissions to such programs in the U.S., 483 are roughly 4 to 8 percentage points less likely than 484 White people to complete treatment for substance-485 related disorders largely due to socio-economic rea-486 sons (Saloner and Lê Cook 2013). Relatedly, because 487 substance abuse treatment programs in the U.S. are 488 linked to the criminal justice system (Kreit 2010), 489 Black and Hispanic adolescents are more likely, com-490 pared to White adolescents, to be discharged from 491 treatment due in part to incarceration (Marotta 492 et al. 2020).⁹

493 The incarceration of a parent can also have pro-494 foundly adverse effects on children (Murphey and 495 Cooper 2015), effects that have clear racial implica-496 tions given that Black children are far more likely 497 than children from other racial groups to have a par-498 ent involved in the criminal justice system (Raphael 499 and Stoll 2009; TSP 2019). But public officials are 500 rarely held accountable for unjust enforcement tac-501 tics-let alone the enforcement of unjust laws-502 because they are protected by indemnification provi-503 sions and the legal doctrine of civil immunity. 504

To address these more specific racial injustices, we 505 call for criminal convictions for nonviolent offenses 506 pertaining to drug use or possession of small quanti-507 ties of non-medical drugs to be expunged, and for 508 those currently serving time for these specific offenses, 509 including those with drug-related parole and proba-510 tion revocations, to be released. Failing that, criminal 511 records for these offenses should be, at the very least, 512 protected from judicial access in future criminal pro-513 ceedings and decoupled from a person's rights and 514 entitlements as a citizen. Furthermore, those who 515 would continue to hold a conviction on their record 516 for these offenses should receive retroactive ameliora-517 tive relief under new decriminalization and/or legal-518 ization laws (Yuen Thompson 2017). 519

Taking a wider perspective, we note that the U.S. commitment to drug prohibition has not only influenced drug policy worldwide (Csete et al. 2016; Coyne

520

521

522

⁷Indeed, violence driven by conflicts within and among gangs and drug-selling crews has, historically, constituted the majority of urban homicide problems (Block and Block 1993; Kennedy, Piehl and Braga 1996; Papachristos 2009), the bulk of which are intraracial (Braga and Brunson 2015). This suggests that the illegal drug market is a major contributing factor to violence within Black communities.

⁸The well-known federal sentencing disparity between powder and crack
cocaine offenses has only recently and partially been addressed by the
Fair Sentencing Act (FSA) of 2010, which reduced the statutory ratio from
100:1 to 18:1, respectively. In 2018, the First Step Act made this reform
retroactive.

⁹The findings of Marotta and colleagues (2020) suggest that Black and Hispanic adolescents were less likely to be discharged when they had been referred by schools and other social institutions, indicating that racial and ethnic disparities in treatment attrition could be mitigated by a combination of *de jure* decriminalization and the enhancement of links between substance abuse treatment programs and social institutions (see footnote 1). 528




Figure 1. Percentage of White vs. Black US population to use an illicit drug/misuse opioids in the past year. Note that use/misuse is similar between the racial groups, with two main exceptions: crack, which has a higher rate of use among Black people, and hallucinogens and methamphetamine, which have higher rates of use among Whites people. Data source: SAMHSA (2018).

and Hall 2017; Koram 2019; Piaggio and Vidwans 2019), but also contributed to human rights abuses and other harms in countries along the illegal drug supply chain (Villar and Cottle 2011; Paley 2014; Piaggio and Vidwans 2019) while providing a power-ful mechanism for increased U.S. "dominance" over poorer countries of the Global South (Telles 2019). There are also implications for gender equity in these countries, as noted by a United Nations task force on women: "Even when women may not directly partici-pate in drug use or the drug trade, they are often responsible for mitigating the associated risks for themselves and for their families, and they are forced to carry the double and triple burden of care when families break apart and community life deteriorates" (UN Women 2014).

Finally, the same harms and racial disparities in U.S. drug enforcement persist in other countries. For example, in England and Wales in 2016/2017, Black people were almost nine times more likely than White people to be stopped and searched for drugs (Shiner et al. 2018, p. 15). They were more likely to be arrested following a stop and search than White people and more likely to be prosecuted (ibid., p. 35). In addition, Black people were con-victed of cannabis possession at almost twelve times

the rate of White people, despite lower rates of selfreported use (*ibid.*, p. 44), and they were over nine times more likely than White people to be sentenced to immediate custody for drug offenses (*ibid.*, p. 45).

DRUG PROHIBITION VIOLATES RIGHTS

Drug prohibition and criminalization not only negatively impact individual users and communities, they may also violate people's rights (Barnett 2009; Fellner 2009). Although some voters and public officials may disapprove of others' personal drug use, people generally have rights over their own bodies that allow them to make decisions not only about their health, but also about the substances they choose to consume, including those drugs that have been legalized in the U.S. and elsewhere, such as alcohol and tobacco. For example, people may use drugs to examine their consciousness, to explore their character, to access and respond to their values, motivations, and desires, and to engage in self-development and self-understanding (Fadiman 2011; Kaelen et al. 2015; Schmid et al. 2015; Liechti, Dolder, and Schmid 2017; Preller et al. 2017; Griffiths et al. 2018; Veit 2018; Earp 2018; Lewis 2020; Earp and Savulescu, in press). Although most drugs,

635 including alcohol, can be used in ways that harm the 636 user, the potential for self-harm does not normally 637 provide adequate grounds for outright prohibition. In 638 general, prohibition conflicts with one's right to con-639 trol what substances one can put into one's body for one's own enjoyment or self-exploration (Huemer 640 2007; Barnett 2009).¹⁰ Moreover, people who freely 641 642 choose to use drugs for personal purposes do not (as 643 such) violate the equal liberty of others and are, there-644 fore, not presumptively liable to civil penalties. As 645 Ostrowski (1990) noted decades ago:

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

Drug prohibition is [the] initiation of physical force against persons engaging in non-violent actions and voluntary transactions involving prohibited drugs. By definition, drug suspects and drug convicts have not been arrested or convicted for having initiated force against the police or private citizens. They would be suspected or convicted of robbery, rape, murder, etc., if they had initiated force against others. (p. 609)

In addition to directly violating some rights, prohibition with criminalization indirectly weakens other rights (Barnett 2009). As demonstrated by the case of Breonna Taylor, for instance, it makes some people more vulnerable to violations not just of their civil liberties but also of their right to life, even when they are not engaged in illegal activity (Husak 1992). For example, drug laws can be used as a pretext for privacy-invading police actions that violate constitutional prohibitions against unreasonable searches (e.g., noknock raids), unreasonable seizures (e.g., civil asset forfeiture) and excessive force (Bertram et al. 1996; Barnett 2009). Finally, to the extent that drug prohibition is enforced in ways that discriminate on the basis of race, it also undermines rights to equal protection of the law, as guaranteed by the Fourteenth Amendment to the U.S. Constitution (Fellner 2009).

¹⁰The right to health may also sometimes be at stake. For some people, prohibited substances such as marijuana, psilocybin, MDMA, LSD, or Ketamine, may be used to treat conditions or manage symptoms in light of the limitations or side-effects associated with conventional medications, or to augment existing therapies (Fadiman and Korb 2015; Griffiths et al. 2016; Mithoefer, Grob and Brewerton 2016; Polito and Stevenson 2019). Although participation in "medical marijuana" ("MMJ") programs varies considerably by state, registry estimates in 2016 suggest that there were around 650,000 registered MMJ users in the U.S. (Fairman 2016), with the majority of participants reported to be in their 40s and 50s (Ilgen et al. 2013; Zaller et al. 2015). However, for those who, for example, cannot access MMJ programs, or whose optimum therapeutic drug is not approved for medical use, drug prohibition impedes their right to access beneficial medical treatment. This problem has been exacerbated by a hostile regulatory and funding climate that has, historically, inhibited research into "illicit" drug treatments and novel drug-assisted therapies, especially those involving MDMA, LSD, or psilocybin (Mithoefer, Grob, and Brewerton 2016; Abbott et al. 2020).

THE BENEFITS OF DECRIMINALIZATION AND LEGAL REGULATION

690 Decriminalizing drug consumption and possession of 691 small amounts of drugs currently deemed to be illicit 692 would not, on the whole, undermine public health or 693 public safety. Rather, decriminalization makes drug 694 use safer and eliminates the harms and injustices asso-695 ciated with arresting and incarcerating drug users. For 696 example, in Portugal, the decriminalization of all rec-697 reational drugs in 2001, together with preventive, 698 treatment, and other harm-reduction efforts plus 699 social reintegration, reduced the harmful effects of 700 arresting and incarcerating drug users, freed up scarce 701 resources in the criminal justice system, and lowered 702 the rates of reported substance use disorders, overdo-703 ses, and drug-related HIV and hepatitis (Greenwald 704 2009; Hughes and Stevens 2010; Kreit 2010; Silvestri 705 2015; DPA 2019). 706

By 2017, Portugal's drug-induced mortality rate 707 among adults was substantially lower than the 708 European average (4 deaths per million compared to 709 22 deaths per million) (EMCDDA 2019). Although 710 the rate of cannabis use in the overall population over 711 a twelve-month period increased from 3.3% in 2001 712 to 5.1% in 2017, use of all other previously illicit 713 drugs (over a twelve-month period) has fallen below 714 2001 levels (Balsa, Vital, and Urbano 2017; DPA 2019; 715 EMCDDA 2019). In addition, since the introduction 716 of these policies, drug offenses, including trafficking 717 and related crimes, have not spiraled upwards 718 (Hughes and Stevens 2010; DPA 2019; SICAD 2019). 719

As the Portugal example shows, when drug users 720 do not fear criminal charges, they are able to seek out 721 medical treatment, mental health care, and social sup-722 port programs, and can access government-approved 723 public information about the harms involved in drug 724 use. In Portugal, the social institutions that focused 725 on harm reduction instead of punishment were also 726 able to engage and help more young people than the 727 criminal system (Silvestri 2015). Additionally, drug 728 decriminalization enabled officials to more effectively 729 deliver housing, health, and employment assistance to 730 populations that would have been more difficult to 731 reach under a prohibitive regime (Kreit 2010; Silvestri 732 2015; DPA 2019). 733

Decriminalization alone, however, does not remove the harms associated with illicit markets (Ostrowski 1990). Such markets do not prioritize consumer safety, and sellers may not be concerned with the age, medical history, or vulnerability of their customers. In addition, decriminalization without legalization would continue to subject people who use drugs to civil 740

741 penalties, including fines, which, in the case of a fine 742 default, could still lead to imprisonment (Hall 1997). 743 Consequently, as we have said, while the first and 744 immediate step should be to decriminalize the per-745 sonal use and possession of small amounts of all drugs 746 currently deemed to be illicit, subsequent steps should 747 find ways to safely and legally regulate the production, 748 storage, distribution, handling, sale, supply, and use of 749 such drugs.

750 Legal regulation offers several advantages over 751 mere decriminalization. It would allow governments 752 to introduce "safe supply" programs for cannabis, 753 opioids such as heroin, stimulants such as cocaine 754 and crystal meth, empathogens such as MDMA, and 755 psychedelics such as psilocybin and LSD in order to 756 curtail the harms associated with illegal markets, 757 end the stigmatization of drug use and drug users, 758 and increase the benefits of responsible drug use 759 and treatment options for substance use disorders 760 (CAPUD 2019). If the drug industry were a regu-761 lated business, governments could provide drug 762 safety-and-hygiene regulations, expanding upon those 763 measures already known to be cost-effective and 764 efficient at reducing harms associated with drug use, 765 such as needle exchange programs (in combination 766 with medication-assisted therapy where appropriate) 767 (Rhodes and Hedrich 2010; Kimber et al. 2010). 768 Accordingly, they would be able to tax drugs 769 according to proper assessment of their respective 770 harms (e.g. Nutt, King, and Phillips 2010), and 771 regulate production, storage, handling, and distribu-772 tion. In collaboration with scientists, regulators, and 773 local authorities, governments could enforce drug 774 safety laws, with qualified officials inspecting pro-775 duction and distribution premises in order to ensure 776 compliance. 777

In addition, state and local authorities could pro-778 vide drug consumption rooms, in which people can 779 use a range of substances through different routes of 780 administration (EMCDDA 2018), as well as clinical-781 like settings for injection drug use. They could pro-782 vide government-approved health information and 783 guidelines relating to safe use, potential harms, and 784 potential benefits. They could also restrict advertising, 785 set appropriate age limits, ban sales to intoxicated 786 people, ensure that public health information is clearly 787 displayed on all packaging, and facilitate and enforce 788 appropriate licensing laws. Such laws could not only 789 limit purchase amounts and purchasing times, but 790 also require special licenses for the purchase of certain 791 drugs deemed to be higher-risk. Of course, we recog-792 nize that whether, and to what extent, these suggested 793

features of a possible regulatory regime will lead to a reduction in relevant harms in practice will, ultimately, depend on the types of enforcement strategies that policymakers adopt to ensure compliance and the rigor with which these strategies are carried out.

All told, we consider a policy of legal regulation to be preferable to decriminalization on its own, which in turn is preferable to criminalization.

IMPLEMENTING DRUG POLICY REFORM

Those seeking to implement drug policy reform need to be aware of the complexities of international law and associated policies. For example, they need to be aware of the U.N.'s international drug control treaties, which have been ratified by the majority of member states, and of the U.N.-based international drug control system, which has been partially responsible for the rise of the "global drug prohibition regime" built around its multi-lateral conventions (Nadelmann 1990). Several U.N. treaties¹¹ prohibit the non-medical use of many of the drugs currently deemed to be illicit, and have been criticized for the very same reasons discussed in this paper (Hall 2018). Given the legalization policies that have come into effect in certain jurisdictions (see footnote 5), the future of these treaties is uncertain (ibid.). However, the question is how to justify domestic policy shifts in light of preexisting international commitments, especially as the global drug prohibition regime has-at least historically-generated a substantial amount of compliance (Finnemore and Sikkink 1998). As Bewley-Taylor (2018) suggests, one option might be to modify certain treaty provisions by means of a "special agreement" among a group of like-minded nations.¹² For instance, if the U.S. sets a precedent for the legalization of the personal possession and use of all drugs deemed to be illicit (plus their regulation as described), and if other influential nations follow suit,

¹¹See: Single Convention on Narcotic Drugs (1961), Convention on Psychotropic Substances (1971), and Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1988). ¹²Another option, one that was pursued by the Obama administration in response to the legalization of cannabis in Washington State and Colorado, is to highlight the "flexibility" reserved to signatory parties in seeking to achieve the treaties' aims (Bennett and Walsh 2014; Bewley-Taylor, Jelsma, and Barrett 2015). With the 2018 proposal of the Strengthening the Tenth Amendment Through Entrusting States ("STATES") Act, which seeks to continue to class cannabis as a Schedule I drug while prohibiting federal law enforcement from prosecuting those in compliance with state law, it seems that the U.S. still considers the "flexibility" approach to treaty compliance to be a politically attractive option (e.g., see Firestone 2019). Given that we call for the legalization and regulation of cannabis as the first of a series of policy changes, the "flexibility" approach could support the implementation of our proposals in the short term.

841

842

843

844

845

846

794

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

847

848

then the treaties in question would likely become "dead letter[s]" (Hall 2018).

Although it is not our aim to defend a particular solution for how a given jurisdiction should navigate the tension between (a) implementing drug policy reform at a local/national level and (b) responding to the demands of international law, we do suggest that if the U.S. is to set a standard for other countries to follow, its reforms must be both evidence-based and ethical-and driven by a firm commitment to racial justice. Indeed, responsible drug policy is about more than just drugs: it is about the flourishing of entire communities. And in this context, it is most especially about the flourishing of Black and Hispanic communities that have been disproportionately harmed by the 862 "war on drugs." Thus, while we ultimately call for the 863 adoption of de jure decriminalization (as qualified 864 above), one way to mitigate racial disparities in pros-865 ecution, conviction, and sentencing rates in the short 866 term is by immediately shifting the focus away from 867 the criminal justice system to a civil "drug court" 868 model (Kreit 2010). This shift would ameliorate harms 869 caused by criminal proceedings and provide less puni-870 tive points of contact to treatment and social services. 871 Such a shift is already widely supported among public 872 health and policy experts (*ibid*.). 873

But we need to be upfront. A full recovery from the failed "war on drugs" will require more than minor shifts and tinkering. Rather, it will require a domestic, postwar "Marshall Plan" consisting of (1) community-building programs focused on poverty alleviation, job creation, improved schooling and housing, and social mobility, thereby reducing the systemic harms that are either caused or made worse by the "war on drugs," mass supervision, and mass incarceration; (2) adequately expanded healthcare, social support programs, and rehabilitation efforts for those who struggle with addiction or other harms associated with drug use or misuse; and (3) realistic, evidencebased educational programs oriented around dissuading minors from drug use, promoting safety among adults who choose to use drugs, and honestly informing the public, policymakers, and other stakeholders about the benefits and risks of using different drugs in different settings.

CONCLUSION

Little of what we argue here is new. The ideas regarding decriminalization, at least, have been the consensus or near consensus of people who use drugs, drug policy experts, harm reduction advocates, criminal justice reformers, and others for decades (Bennett 900 901 1974; Maloff 1981; Farr 1990; Duke 1995; Kerr et al. 902 2006; Stimson 2007; WHO 2014, 2017; UN 2019). 903 Here, we simply add our support as bioethicists and 904 allied professionals to this long-proposed policy 905 change while calling for its extension through to legal 906 regulation of all drugs currently deemed to be illicit, 907 and highlighting the implications for systemic racism 908 (Danis, Wilson, and White 2016). As we have 909 observed, the "war on drugs" has disproportionately 910 targeted historically vulnerable communities. In par-911 ticular, Black and Hispanic communities have borne 912 the brunt of this misguided "war" with its unjust drug 913 laws coupled with discriminatory policing, prosecu-914 tion, conviction, and sentencing. The moral impera-915 tive now is for policymakers to act. Drug prohibition 916 and criminalization have been costly and ineffective 917 since their inception (Miron and Zwiebel 1995; 918 Sterling 2006; Miron 2018): it is time for these failed 919 policies to end. The first step is to decriminalize the 920 personal use and possession of small amounts of all 921 drugs currently deemed to be illicit and to legalize 922 and regulate cannabis. Policymakers should pursue 923 these changes without further delay. 924

ORCID

Brian D. Earp (D http://orcid.org/0000-0001-9691-2888 Jonathan Lewis D http://orcid.org/0000-0001-8342-1051 925

926

927

928

929

930

931

946

REFERENCES

- 932 Abbott, K. L., K. S. Gill, P. C. Flannery, D. M. Boothe, M. 933 Dhanasekaran, and S. Pondugula. 2020. Nothing ventured, nothing gained: Regulations cripple potentially life-934 saving research of illicit substances. ACS Chemical 935 Neuroscience 11 (10):1382-4. 10.1021/acschemneuro. 936 0c00241. 937
- ACLU (American Civil Liberties Union). 2014. War comes 938 home: The excessive militarization of american policing. 939 Washington, DC: American Civil Liberties Union. 940 https://www.aclu.org/issues/criminal-law-reform/reform-941 ing-police/war-comes-home.
- Ahern, J., J. Stuber, and S. Galea. 2007. Stigma, discrimin-942 ation and the health of illicit drug users. Drug and 943 Alcohol Dependence 88 (2-3):188-96. doi: 10.1016/j.dru-944 galcdep.2006.10.014. 945
- Alexander, M. 2010. The new Jim Crow: Mass incarceration in the age of colorblindness. New York: The New Press.
- 947 Anomaly, J. 2013. Collective action and individual choice: 948 Rethinking how we regulate narcotics and antibiotics. 949 Journal of Medical Ethics 39 (12):752-6. 10.1136/ 950 medethics-2012-101160.
- Balsa, C., C. Vital, and C. Urbano. 2017. IV Inquérito 951 Nacional ao Consumo de Substâncias Psicoativas na 952

- 953População Geral, Portugal 2016/17. I relatório final.954Lisbon: CICS.NOVA.
- Barnett, R. E. 2009. The harmful side effects of drug prohibition. Utah Law Review 1:11–34. https://scholarship.law. georgetown.edu/facpub/817/.
- 957 Beckett, K., K. Nyrop, and L. Pfingst. 2006. Race, drugs, and policing: Understanding disparities in drug delivery arrests. *Criminology* 44 (1):105–37. doi: 10.1111/j.1745-9125.2006.00044.x.
- Bennett, J. S. 1974. Le Dain Commission of Inquiry into the Non-medical Use of Drugs tables fourth and final report. *Canadian Medical Association Journal* 110 (1):105–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1947221/.
 Bennett, W., and L. Walds, 2014. Marijuga Jacobiettow in
- Bennett, W., and J. Walsh. 2014. Marijuana legalization is 965 an opportunity to modernize international drug treaties. 966 Washington, DC: Center for Effective Public 967 Management at Brookings. https://www.brookings.edu/ 968 research/marijuana-legalization-is-an-opportunity-tomodernize-international-drug-treaties/. 969
- Bertram, E., M. Blachman, K. Sharpe, and P. Andreas. 1996.
 Drug war politics: The price of denial. Berkeley and Los Angeles, CA: University of California Press.
- 972 Bewley-Taylor, D. R. 2018. Canada, cannabis legalization and uncertainty around the United Nations drug control conventions. *Addiction* 113 (7):1226–8.
- Bewley-Taylor, D. R., M. Jelsma, and D. Barrett. 2015. Fatal attraction: Brownfield's flexibility doctrine and global drug policy reform. *Huffpost*, January 18, 2015. https://www.huffingtonpost.co.uk/damon-barett/drug-policy-reform_b_6158144.html.
- 979 Blanken, P., W. van den Brink, V. M. Hendriks, I. A. 980 Huijsman, M. G. Klous, E. J. Rook, J. S. Wakelin, C. 981 Barendrecht, J. H. Beijnen, and J. M. van Ree. 2010. 982 Heroin-assisted treatment in the Netherlands: History, 983 findings, and international context. European Neuropsychopharmacology 20 (2):S105-S8. doi: 10.1016/ 984 S0924-977X(10)70001-8. 985
- Block, C. R., and R. Block. 1993. Street gang crime in Chicago. Washington, DC: National Institute of Justice. https://pdfs.semanticscholar.org/17bf/40fc952dc172cf9b0a 008675bdf827c3773d.pdf.
- Braga, A. A., and R. K. Brunson. 2015. The police and public discourse on 'black-on-black' violence. Laurel, MD:
 National Institute of Justice. https://www.ncjrs.gov/pdffiles1/nij/248588.pdf.
- Buchman, D. Z., P. Leece, and A. Orkin. 2017. The epidemic as stigma: The bioethics of opioids. *The Journal of Law, Medicine & Ethics* 45 (4):607–20. doi: 10.1177/1073110517750600.
- California Community Reinvestment Grants Program. 2019.
 California community reinvestment grants program.
 Accessed September 16, 2020. https://business.ca.gov/california-community-reinvestment-grants-program/.
- Campos, I. 2012. Home grown: Marijuana and the origins of Mexico's war on drugs. Chapel Hill, NC: University of North Carolina Press.
- 1002 CAPUD (Canadian Association of People Who Use Drugs).
 1003 2019. Safe supply concept document. Canadian
 1004 Association of People Who Use Drugs. https://vancouver.
 1005 ca/files/cov/capud-safe-supply-concept-document.pdf.

Chin, G. J. 2002. Race, the war on drugs, and the collateral
consequences of criminal conviction. Journal of Gender,
Race and Justice 6 (2):253–76.1006
1007Clear, T. R. 2007. Imprisoning communities: How mass
incrementies works disclosure disclosure

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

- incarceration makes disadvantaged communities worse. Oxford: Oxford University Press.
- Clifford, P. R. 1992. Drug use, drug prohibition and minority communities. *The Journal of Primary Prevention* 12 (4):303–16. doi: 10.1007/BF01325177.
- Colorado Department of Education. 2018. Marijuana tax revenue and education. Accessed September 16, 2020. https://cosfp.org/wp-content/uploads/Marijuana-Tax-Revenue-and-Education-FAQ-_-CDE-May-2018.pdf.
- Coyne, C. J., and A. R. Hall. 2017. Four decades and counting: The continued failure of the war on drugs. Policy Analysis 811. Washington, DC: Cato Institute. https:// www.cato.org/sites/cato.org/files/pubs/pdf/pa-811updated.pdf.
- Csete, J., A. Kamarulzaman, M. Kazatchkine, F. Altice, M. Balicki, J. Buxton, J. Cepeda, M. Comfort, E. Goosby, J. Goulão, et al. 2016. Public health and international drug policy. *The Lancet* 387 (10026):1427–80. doi: 10.1016/S0140-6736(16)00619-X.
- Danis, M., Y. Wilson, and A. White. 2016. Bioethicists can and should contribute to addressing racism. *The American Journal of Bioethics* 16 (4):3-12. 10.1080/ 15265161.2016.1145283.
- Del Toro, J., T. Lloyd, K. S. Buchanan, S. J. Robins, L. Z. Bencharit, M. G. Smiedt, K. S. Reddy, E. R. Pouget, E. M. Kerrison, and P. A. Goff. 2019. The criminogenic and psychological effects of police stops on adolescent black and Latino boys. *Proceedings of the National Academy of Sciences of the United States of America* 116 (17):8261–8.
- DPA (Drug Policy Alliance). 2015. Racial and ethnic impact statements. New York: Drug Policy Alliance. http://www. drugpolicy.org/sites/default/files/DPA_FactSheet_Racial_ and_Ethnic_Impact_Statements_July2015.pdf.
- DPA (Drug Policy Alliance). 2018. From prohibition to progress: A status report on marijuana legalization. New York: Drug Policy Alliance. https://www.drugpolicy.org/ sites/default/files/dpa_marijuana_legalization_report_ feb14_2018_0.pdf.
- DPA (Drug Policy Alliance). 2019. Drug decriminalization in Portugal: Learning from a health and human-centered approach. New York: Drug Policy Alliance. https://www. drugpolicy.org/sites/default/files/dpa-drug-decriminalization-portugal-health-human-centered-approach_0.pdf.
- Duke, S. B. 1995. Drug prohibition: An unnatural disaster. Connecticut Law Review 27 (2):571-612.
- Duke, S. B. 2009. Mass imprisonment, crime rates, and the drug war: A penological and humanitarian disgrace. *Connecticut Public Interest Law Journal* 9 (1):17–36. https://heinonline.org/HOL/LandingPage?handle=hein. journals/cpilj9&div=5&id=&page=.
- Earp, B. D. 2018. Psychedelic moral enhancement. *Royal Institute of Philosophy Supplement* 83:415–39. doi: 10. 1017/S1358246118000474.[10.1017/S1358246118000474]
- Earp, B. D., and J. Savulescu. In Press. Psychedelic relationship enhancement. *Philosophy and Public Issues*. https:// www.researchgate.net/publication/344875872
- EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). 2018. Drug consumption rooms: An

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1142

1059overview of provision and evidence. Lisbon: European1060Monitoring Centre for Drugs and Drug Addiction.1061https://www.emcdda.europa.eu/publications/pods/drug-
consumption-rooms_en.1062Drugt (Drugt)

- 1062EMCDDA (European Monitoring Centre for Drugs and
Drug Addiction). 2019. Portugal country drug report
2019. Lisbon: European Monitoring Centre for Drugs
and Drug Addiction. https://www.emcdda.europa.eu/sys-
tem/files/publications/11331/portugal-cdr-2019_0.pdf.
- Epp, C. R., S. Maynard-Moody, and D. Haider-Markel.
 2017. Beyond profiling: The institutional sources of racial disparities in policing. *Public Administration Review* 77 (2):168–78. doi: 10.1111/puar.12702.
 Fadiman, J. 2011. *The psychedelic explorer's guide: Safe.*
 - Fadiman, J. 2011. The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys. Rochester, VT: Park Street Press.

1071

1072

1073

1074

1079

1080

1099

1100

1101

1102

- Fadiman, J., and S. Korb. 2015. Microdosing psychedelics. Accessed September 13, 2020. https://sites.google.com/ view/microdosingpsychedelics/.
- 1075 Fairman, B. J. 2016. Trends in registered medical marijuana participation across 13 US States and District of Columbia. *Drug and Alcohol Dependence* 159:72–9. doi: 10.1016/j.drugalcdep.2015.11.015.
 - Farr, K. A. 1990. Revitalizing the drug decriminalization debate. *Crime & Delinquency* 36 (2):223-37. doi: 10.1177/0011128790036002003.
- Fellner, J. 2009. Race, drugs, and law enforcement in the united states. *Stanford Law & Policy Review* 20: 257–92.
 https://law.stanford.edu/publications/race-drugs-law-enforcement-united-states/.
- Finnemore, M., and K. Sikkink. 1998. International norm dynamics and political change. *International Organization* 52 (4):887–917. doi: 10.1162/002081898550789.[10.1162/ 002081898550789]
- 1088Firestone, T. 2019. "Legalization vs. International Drug1089Treaties: Is the STATES Act the Answer?" Global1090Cannabis Compliance Blog, April 30, 2019. https://global-
cannabiscompliance.bakermckenzie.com/2019/04/30/legal-
ization-vs-international-drug-treaties-is-the-states-act-the-
answer/
- 1093Flanigan, J. 2017. Pharmaceutical freedom: Why patients1094have a right to self-medicate. Oxford: Oxford University1095Press.
- Fryer Jr, R. G. 2019. An empirical analysis of racial differences in police use of force. *Journal of Political Economy* 127 (3):1210–61. doi: 10.1086/701423.
 Ghandnoosh, N. 2015. *Black lives matter: Eliminating racial*
 - Ghandnoosh, N. 2015. Black lives matter: Eliminating racial inequity in the criminal justice system. Washington, DC: The Sentencing Project.
 - Greenwald, G. 2009. Drug decriminalization in Portugal: Lessons for creating fair and successful drug policies. Washington, DC: Cato Institute.
- 1103 Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. 1104 Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produ-1105 ces substantial and sustained decreases in depression and 1106 anxiety in patients with life-threatening cancer: A 1107 randomized double-blind trial. Journal of 1108 Psychopharmacology 30 (12):1181-97. 10.1177/02698811 1109 1667551.
- 1110Griffiths, R. R., M. W. Johnson, W. A. Richards, B. D.1111Richards, R. Jesse, K. A. MacLean, F. S. Barrett, M. P.

Cosimano, and M. A. Klinedinst. 2018. Psilocybin-occa-
sioned mystical-type experience in combination with
meditation and other spiritual practices produces endur-
ing positive changes in psychological functioning and in
trait measures of prosocial attitudes and behaviors.
Journal of Psychopharmacology 32 (1):49–69. doi: 10.
1177/0269881117731279.1112
1113
1114
1115
1116
1117fall, W. 1997. The recent Australian debate about the pro-1112

- Hall, W. 1997. The recent Australian debate about the prohibition on cannabis use. *Addiction* 92 (9):1109–15. doi: 10.1111/j.1360-0443.1997.tb03668.x.
- Hall, W. 2018. The future of the international drug control system and national drug prohibitions. *Addiction* 113 (7):1210–23.
- Harding, D. J. 2019. On the outside: Prisoner reentry and reintegration. Chicago, IL: University of Chicago Press.
- Hart, C. L. 2013. High price. New York: HarperCollins.

Hart, C. L. 2020. Exaggerating harmful drug effects on the brain is killing black people. *Neuron* 107 (2):215–8. doi: 10.1016/j.neuron.2020.06.019.

- Hoss, A. 2019. Legalizing harm reduction. *Ohio State Law Journal* 80 (4):825–39. 10.2139/ssrn.3439679.
- Huemer, M. 2007. America's unjust drug war. In: *The right thing to do*, ed. James Rachels and Stuart Rachels, 133–143. New York: McGraw Hill.
- Hughes, C., A. Ritter, J. Chalmers, K. Lancaster, M. Barratt, and V. Moxham-Hall. 2016. Decriminalisation of drug use and possession in Australia A briefing note. Sydney: Drug Policy Modelling Program, NDARC, UNSW Australia. https://ndarc.med.unsw.edu.au/resource/ decriminalisation-drug-use-and-possession-australia-brief-ing-note.
 Hughes, C., A. Ritter, J. Chalmers, K. Lancaster, M. Barratt, 1132
 1133
 1134
 1135
 1136
 1136
 1137
 1138
- Hughes, C. E., and A. Stevens. 2010. What can we learn
from the Portuguese decriminalization of illicit drugs?1139The British Journal of Criminology 50 (6):999–1022. doi:114010.1093/bjc/azq038.1141
- Husak, D. N. 1992. *Drugs and rights*. Cambridge: Cambridge University Press.
- Ilgen, M. A., K. Bohnert, F. Kleinberg, M. Jannausch,
A. S. B. Bohnert, M. Walton, and F. C. Blow. 2013.
Characteristics of adults seeking medical marijuana certi-
fication. Drug and Alcohol Dependence 132 (3):654–9.
doi: 10.1016/j.drugalcdep.2013.04.019.1143
1143
1144
- Kaelen, M., F. S. Barrett, L. Roseman, R. Lorenz, N. Family, M. Bolstridge, H. V. Curran, A. Feilding, D. J. Nutt, and R. L. Carhart-Harris. 2015. LSD enhances the emotional response to music. *Psychopharmacology* 232 (19):3607–14. doi: 10.1007/s00213-015-4014-y.
- Kennedy, D. M., A. M. Piehl, and A. A. Braga. 1996. Youth violence in Boston: Gun markets, serious youth offenders, and a use reduction strategy. Law and Contemporary Problems 59 (1):147–96. doi: 10.2307/1192213.
 Kerr, T. W. Smell, W. Beacce, D. Dougles, A. Bierre, and F. 1155
- Kerr, T., W. Small, W. Peeace, D. Douglas, A. Pierre, and E. Wood. 2006. Harm reduction by a 'user-run' organization: A case study of the Vancouver Area Network of Drug Users (VANDU). *International Journal of Drug Policy* 17 (2):61–9. doi: 10.1016/j.drugpo.2006.01.003.
 1153
- Kimber, J., N. Palmateer, S. Hutchinson, M. Hickman, D. Goldberg, and T. Rhodes. 2010. Harm reduction among injecting drug users Evidence of effectiveness. In *Harm Reduction: Evidence, Impacts and Challenges*, ed. Tim Rhodes and Dagmer Hedrich, 115–163. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.

- Koch, D. W., J. Lee, and K. Lee. 2016. Coloring the war on drugs: Arrest disparities in black, brown, and white. *Race* and Social Problems 8 (4):313–25. doi: 10.1007/s12552-016-9185-6.
- 1108 1169 Koram, K. 2019. Introduction. In *The war on drugs and the global colour line*, ed. Kojo Koram. London: Pluto.
- Kraska, P. B., and V. E. Kappeler. 1997. Militarizing American police: The rise and normalization of paramilitary units. Social Problems 44 (1):1–18. doi: 10.2307/ 3096870.
- Kreit, A. 2010. The decriminalization option: Should states consider moving from a criminal to a civil drug court model? University of Chicago Legal Forum 2010 (1): 299–336.
- 1177 Lewis, J. 2020. Autonomy and the limits of cognitive enhancement. *Bioethics*. (online ahead of print). doi: 10.
 1111/bioe.12791.
- Liechti, M. E., P. C. Dolder, and Y. Schmid. 2017. Alterations of consciousness and mystical-type experiences after acute LSD in humans. *Psychopharmacology* 234 (9–10):1499–510. 10.1007/s00213-016-4453-0.
- Lopez, G. 2014. "The entire war on drugs is racist." *Vox.*July 27, 2014. https://www.vox.com/2014/7/27/5940783/
 prohibition-marijuana-legalization-pot-weed-racism-newyork-times.
- 1186
 Luna, E. 2016. Drug war and peace. UC Davis Law Review

 1187
 50 (2):813-95.
- 1188 Lynch, M. 2019. Place, race, and variations in federal criminal justice practices. *Ohio State Journal of Criminal Law* 17:167–84. https://ssrn.com/abstract=3543250.
- Lynch, M., and M. Omori. 2018. Crack as proxy: Aggressive federal drug prosecutions and the production of black-white racial inequality. *Law & Society Review* 52 (3):773-809. doi: 10.1111/lasr.12348.
- MacCoun, R. J. 1993. Drugs and the law: A psychological analysis of drug prohibition. *Psychological Bulletin* 113 (3):497–512. doi: 10.1037/0033-2909.113.3.497.
- Mallea, P. 2014. *The war on drugs: A failed experiment*. Toronto: Dundurn.
- 1198Maloff, D. 1981. A review of the effects of the decriminal-
ization of marijuana. Contemporary Drug Problems 101200(3):307-22. https://heinonline.org/HOL/LandingPage?
handle=hein.journals/condp10&div=27&id=&page=.
- Manderson, D. 1999. Symbolism and racism in drug history and policy. *Drug and Alcohol Review* 18 (2):179–86. doi: 10.1080/09595239996617.
- 1204Marlan, D. 2020. Beyond cannabis: Psychedelic decriminal-
ization and social justice. Lewis & Clark Law Review 231206(3):851-92. https://ssrn.com/abstract=3438542.
- Marotta, P. L., M. Tolou-Shams, R. M. Cunningham-Williams, D. Malik Washington, and D. Voisin. 2020. Racial and ethnic disparities, referral source and attrition from outpatient substance use disorder treatment among adolescents in the United States. *Youth & Society*. (online ahead of print). doi: 10.1177/0044118X20960635
- Mauer, M., and R. King. 2007. A 25-year quagmire: The war on drugs and its impact on American Society. Washington, DC: The Sentencing Project. https://www. sentencingproject.org/publications/a-25-year-quagmirethe-war-on-drugs-and-its-impact-on-american-society/.
- 1216 Miller, R. J., and F. Stuart. 2017. Carceral citizenship: Race,
- 1217 rights and responsibility in the age of mass supervision.

Theoretical Criminology 21 (4):532–48. doi: 10.1177/ 1362480617731203.

- Miron, J. A. 2018. The budgetary effects of ending drug prohibition. *Tax and Budget Bulletin* 83. Washington, DC: Cato Institute. https://www.cato.org/sites/cato.org/ files/pubs/pdf/tbb-83.pdf.
- Miron, J. A., and J. Zwiebel. 1995. The economic case against drug prohibition. *Journal of Economic Perspectives* 9 (4):175–92. doi: 10.1257/jep.9.4.175.
- Mitchell, O., and M. S. Caudy. 2015. Examining racial disparities in drug arrests. *Justice Quarterly* 32 (2):288–313. doi: 10.1080/07418825.2012.761721.
- Mithoefer, M. C., C. S. Grob, and T. D. Brewerton. 2016.
 Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. *The Lancet. Psychiatry* 3 (5):481–8. doi: 10.1016/S2215-0366(15)00576-3.
- Murphey, D., and P. M. Cooper. 2015. *Parents behind bars: What happens to their children?* Washington, DC: Child Trends. https://www.childtrends.org/wp-content/uploads/ 2015/10/2015-42ParentsBehindBars.pdf.
- Musto, D. F. 1999. *The American disease: Origins of narcotic control.* 3rd ed. Oxford: Oxford University Press.
- Nadelmann, E. 1990. Global prohibition regimes: The evolution of norms in international society. *International Organization* 44 (4):479–526. doi: 10.1017/ S0020818300035384.
- Natapoff, A. 2020. Atwater and the misdemeanor carceral state. *Harvard Law Review Forum* 133 (6):147–78.
- Nellis, A. 2016. The color of justice: Racial and ethnic disparity in state prisons. Washington, DC: The Sentencing Project. https://www.sentencingproject.org/publications/ color-of-justice-racial-and-ethnic-disparity-in-stateprisons/.
- Netherland, J., and H. B. Hansen. 2016. The war on drugs that wasn't: Wasted whiteness, "dirty doctors," and race in media coverage of prescription opioid misuse. *Culture*, *Medicine and Psychiatry* 40 (4):664–86. 10.1007/s11013-016-9496-5.
- Nunn, K. B. 2002. Race, crime and the pool of surplus criminality: Or why the war on drugs was a war on blacks. *Journal of Gender, Race and Justice* 6 (2):381–446.
- Nutt, D. J., L. A. King, and L. D. Phillips. 2010. Drug harms in the UK: A multicriteria decision analysis. *The Lancet* 376 (9752):1558–65. doi: 10.1016/S0140-6736(10)61462-6.
- Omori, M. 2019. 'Nickel and dimed' for drug crime: Unpacking the process of cumulative racial inequality. *The Sociological Quarterly* 60 (2):287–313. doi: 10.1080/ 00380253.2018.1526049.
- Onyeador, I. N., N. M. Daumeyer, J. M. Rucker, A. Duker, M. W. Kraus, and J. A. Richeson. 2020. Disrupting beliefs in racial progress: Reminders of persistent racism alter perceptions of past, but not current, racial economic equality. *Personality and Social Psychology Bulletin*. (online ahead of print). doi: 10.1177/0146167220942625.
- Ostrowski, J. 1990. The moral and practical case for drug legalization. *Hofstra Law Review* 18:607–702.
- Ostrowski, J. 1991. Answering the critics of drug legalization. *Notre Dame Journal of Law, Ethics & Public Policy* 5 (3):823–52.
- Paley, D. 2014. Drug war capitalism. Oakland, CA: AK Press.

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1369

1370

Papachristos, A. V. 2009. Murder by structure: Dominance relations and the social structure of gang homicide. *American Journal of Sociology* 115 (1):74–128. doi: 10. 2139/ssrn.855304.
Dentitie L. 2009. With a structure of the structure of the structure of the social structur

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1322

1323

- Petersilia, J. 2009. When prisoners come home: Parole and prisoner reentry. Oxford: Oxford University Press.
- Petteruti, A., and N. Walsh. 2008. Jailing communities: The impact of jail expansion and effective public safety strategies. Washington, DC: Justice Policy Institute. http:// www.justicepolicy.org/research/1946.
- Pfaff, J. F. 2017. Locked in. New York: Basic Books. https:// www.basicbooks.com/titles/john-pfaff/locked-in/ 9780465096916/.
 - Piaggio, A., and P. Vidwans. 2019. The cost and consequences of the war on drugs. New York: Human Rights Foundation. http://fileserver.idpc.net/library/the-cost-andconsequence.pdf.
 - Pickard, H. 2020. What we're not talking about when we talk about addiction. *Hastings Center Report* 50 (4):37-46.
 - Polito, V., and R. J. Stevenson. 2019. A systematic study of microdosing psychedelics. *PLoS ONE* 14 (2):e0211023. 10. 1371/journal.pone.0211023.
- Preller, K. H., M. Herdener, T. Pokorny, A. Planzer, R. Kraehenmann, P. Stämpfli, M. E. Liechti, E. Seifritz, and F. X. Vollenweider. 2017. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. *Current Biology* 27 (3):451–7. 10. 1016/j.cub.2016.12.030.
 - Provine, D. M. 2007. Unequal under law: Race in the war on drugs. Chicago, IL: University of Chicago Press.
- Raphael, Steven, and Michael S. Stoll, eds. 2009. Do prisons make us safer? The benefits and costs of the prison boom. New York: Russell Sage Foundation.
- Reuter, P. 2009. Systemic violence in drug markets. *Crime, Law and Social Change* 52 (3):275–84. doi: 10.1007/ s10611-009-9197-x.
- Rhodes, T., and D. Hedrich. 2010. Harm reduction and the mainstream. In *Harm reduction: Evidence, impacts and challenges*, ed. Tim Rhodes and Dagmer Hedrich, 19–33. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
 - Room, R., and P. Reuter. 2012. How well do international drug conventions protect public health? *The Lancet* 379 (9810):84–91. doi: 10.1016/S0140-6736(11)61423-2.
- Rosino, M. L., and M. W. Hughey. 2018. The war on drugs, racial meanings, and structural racism: A holistic and reproductive approach. *American Journal of Economics* and Sociology 77 (3-4):849-92. doi: 10.1111/ajes.12228.
- Saloner, B., and B. Lê Cook. 2013. Blacks and hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. *Health Affairs* (*Project Hope*) 32 (1):135–45. 10.1377/hlthaff.2011.0983.
- SAMHSA (Substance Abuse and Mental Health Services Administration. (2018). Results from the 2018 National Survey on Drug Use and Health (NSDUH): Detailed tables (section 1: Illicit drug use/misuse tables - 1.1 to 1.122). Rockville, MD: Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/ sites/default/files/cbhsq-reports/NSDUHDetailedTabs 2018R2/NSDUHDetTabsSect1pe2018.htm.
 - Schmid, Y., F. Enzler, P. Gasser, E. Grouzmann, K. H. Preller, F. X. Vollenweider, R. Brenneisen, F. Müller, S.

Borgwardt, and M. E. Liechti. 2015. Acute effects of lyser-
gic acid diethylamide in healthy subjects. Biological
Psychiatry 78 (8):544–53. 10.1016/j.biopsych.2014.11.015.1324
1325
1326

- Shiner, M., Z. Carre, R. Delsol, and N. Eastwood. 2018. The
colour of injustice: 'Race', drugs and law enforcement in
England and Wales. London: International Drug Policy
Unit (IDPU). https://www.stop-watch.org/uploads/docu-
ments/The_Colour_of_Injustice.pdf.1320
1321
1328
1329
- SICAD (Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências). 2019. Relatório Anual 2018
 - A Situação do País em Matéria de Drogas e Toxicodependências. Lisbon: SICAD. http://www.sicad.pt/ BK/Publicacoes/Lists/SICAD_PUBLICACOES/ Attachments /162/Relatorio_Anual_2018_A_SituacaoDo PaisEmMateriaDeDrogas_e_Toxicodependencias.pdf
- Silvestri, A. 2015. Gateways from crime to health: The Portuguese drug commissions. London: Winston Churchill Memorial Trust. https://www.wcmt.org.uk/fellows/ reports/drug-use-health-issue-learning-portuguesepolicies.
- Single, E., P. Christie, and R. Ali. 2000. The impact of cannabis decriminalisation in Australia and the United States. *Journal of Public Health Policy* 21 (2):157–86. doi: 10.2307/3343342.
- Small, D. 2001. The war on drugs is a war on racial justice. Social Research 68 (3):896–903.
- Smith, W. R., and D. Sisti. 2020. Ethics and ego dissolution: The case of psilocybin. *Journal of Medical Ethics*. (online ahead of print). 10.1136/medethics-2020-106070.
- Spohn, C. C. 2000. Thirty years of sentencing reform: The quest for a racially neutral sentencing process. *Criminal Justice* 3:427–501.
- Steffensmeier, D., and S. Demuth. 2000. Ethnicity and sentencing outcomes in U.S. Federal Courts: Who is punished more harshly? *American Sociological Review* 65 (5): 705–29. doi: 10.2307/2657543.
- Steffensmeier, D., and S. Demuth. 2001. Ethnicity and judges' sentencing decisions: Hispanic-Black-white comparisons. *Criminology* 39 (1):145–78. doi: 10.1111/j.1745-9125.2001.tb00919.x.
- Sterling, E. E. 2004. Drug policy: A challenge of values. Journal of Religion & Spirituality in Social Work 23 (1/2): 51–81. doi: 10.1300/J377v23n01_04.
- S1-81. doi: 10.1300/J37/V23001_04.1360Sterling, E. E. 2006. Getting justice off its junk food diet:
Getting tough on cocaine traffickers and fixing the racial
disparity of crack prosecutions. White Paper. The
Criminal Justice Policy Foundation. www.cjpf.org/
1363
Getting_Justice_Off_Its_Junk_Food_Diet.pdf.1360
- Stimson, G. V. 2007. "Harm reduction-coming of age": A local movement with global impact. *The International Journal on Drug Policy* 18 (2):67–9. 10.1016/j.drugpo. 2006.12.012.
 Telles A. C. 2019. Mothers warriors and lords: Gender(ed) 1368
- Telles, A. C. 2019. Mothers, warriors and lords: Gender(ed) cartographies of the US war on drugs in Latin America. *Contexto Internacional* 41 (1):15–37. doi: 10.1590/s0102-8529.2019410100002.
- 8529.2019410100002.
 Thorne Harbour Health. 2017. Joint statement opposing the miscellaneous amendment bill 2017. Abbotsford, Victoria: 1372
 Thorne Harbour Health.
- Thoumi, F. E. 2003. Illegal drugs, economy, and society in the Andes. Baltimore, MD: Johns Hopkins University Press. 1376

- 1377 Thoumi, F. E. 2010. The relationship between illegal drugs and violence: Is there a cause and effect? *Teresa Lozano Long Institute of Latin American Studies (LLILAS)* 5: 38–39. http://hdl.handle.net/2152/61986.
- Todd, T. 2018. The benefits of marijuana legalization and
regulation. Berkeley Journal of Criminal Law 23 (1):
99–119.
- 1383TSP (The Sentencing Project. 2018. Report to the United1384Nations on racial disparities in the U.S. criminal justice1385system. The Sentencing Project. https://www.sentencing-1386project.org/publications/un-report-on-racial-disparities/
- TSP (The Sentencing Project. 2019. Incarcerated Women and Girls. The Sentencing Project. https://www.sentencingproject.org/publications/incarcerated-women-andgirls/
- Turner, J., and J. Dawkar. 2014. Racial disparities in sentencing. New York: American Civil Liberties Union. https:// www.aclu.org/sites/default/files/assets/141027_iachr_ racial_disparities_aclu_submission_0.pdf.
- UN (United Nations System Coordination Task Team on the Implementation of the UN System Common Position on Drug-related Matters). 2019. What we have learned over the last ten years: A summary of knowledge acquired and produced by the un system on drug-related matters.
 Vienna: United Nations. https://www.unodc.org/documents/commissions/CND/2019/Contributions/UN_
- 1400Entities/What_we_have_learned_over_the_last_ten_1401years_-_14_March_2019_-_w_signature.pdf.
- UN Women (United Nations Women Task Force on Transnational Organized Crime and Drug Trafficking as Threats to Security and Stability). 2014. A gender perspective on the impact of drug use, the drug trade, and drug control regimes. Vienna: United Nations. https://www. unodc.org/documents/ungass2016/Contributions/UN/ Gender_and_Drugs_-_UN_Women_Policy_Brief.pdf.
- Vagins, D., and J. McCurdy. 2006. Cracks in the system: 20 years of the unjust federal crack cocaine law. New York: American Civil Liberties Union. https://www.aclu.org/ other/cracks-system-20-years-unjust-federal-crackcocaine-law.
- 1412 Veit, W. 2018. Cognitive enhancement and the threat of inequality. *Journal of Cognitive Enhancement* 2 (4): 404-10. doi: 10.1007/s41465-018-0108-x.

- Villar, O., and D. Cottle. 2011. Cocaine, death squads, and the war on terror: Us imperialism and class struggle in Colombia. New York: NYU Press.
- Wainwright, T. 2016. *Narconomics: How to run a drug cartel.* New York: PublicAffairs.
- Washington State Liquor and Cannabis Board. 2019. Annual report fiscal year 2019. Olympia, WA: Washington State Liquor and Cannabis Board. https:// lcb.wa.gov/sites/default/files/publications/annual_report/ 2019-annual-report-final2.pdf.
- Weitzer, R., and R. K. Brunson. 2015. Policing different racial groups in the United States. *Cahiers Politiestudies* 6 (35):129–45.
- Western, B. 2002. The impact of incarceration on wage mobility and inequality. *American Sociological Review* 67 (4):526–46. doi: 10.2307/3088944.
- Western, B., and B. Pettit. 2010. Incarceration and social inequality. *Daedalus* 139 (3):8–19. doi: 10.1162/DAED_a_00019.
- WHO (World Health Organization). 2014. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization. https://www.who.int/hiv/pub/guidelines/ keypopulations/en/.
- WHO (World Health Organization). 2017. Joint United Nations statement on ending discrimination in health care settings. Geneva: World Health Organization. https:// www.who.int/en/news-room/detail/27-06-2017-jointunited-nations-statement-on-ending-discrimination-inhealth-care-settings.
- Yuen Thompson, B. 2017. 'Good moral characters': How drug felons are impacted under state marijuana legalization laws. *Contemporary Justice Review* 20 (2):211–26. doi: 10.1080/10282580.2017.1307109
- Zaller, N., A. Topletz, S. Frater, G. Yates, and M. Lally. 2015. Profiles of medicinal cannabis patients attending compassion centers in Rhode Island. *Journal of Psychoactive Drugs* 47 (1):18–23. doi: 10.1080/02791072. 2014.999901.
- Zigon, J. 2019. A war on people: Drug user politics and a new ethics of community. Oakland, CA: University of California Press.
- 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477
- 1478
- 1479
- 1480
- 1481 1482

1415

1416

1417 1418

1419

1420

1421

1422

1423

1424

1425

1426

Appendix

Authors: Bioethicists and Allied Professionals for Drug Policy Reform

1487	
1488	Brian D. Earp*
1489	Associate Director,
1490	Yale-Hastings Program in Ethics and Health Policy
1491	Yale University & The Hastings Center
1492	Correspondence: brian.earp@yale.edu Jonathan Lewis*
1493	Postdoctoral Fellow in Bioethics
	Dublin City University
1494	Correspondence: jonathan.lewis@dcu.ie
1495	Jonathan Anomaly Associate Director,
1496	Philosophy, Politics & Economics
1497	University of Pennsylvania Gabriela Arguedas-Ramírez
1498	Associate Professor
1499	Philosophy and Women's Studies
1500	Universidad de Costa Rica lain Brassington
1501	Senior Lecturer in Law
1502	University of Manchester
1503	Lori Bruce Director, Sherwin B. Nuland Summer Institute in Bioethics;
1504	Associate Director,
1505	Interdisciplinary Center for Bioethics
1505	Yale University; Chair, Community Bioethics Forum
1500	Yale School of Medicine
	Allen Buchanan
1508	James B. Duke Distinguished Professor Emeritus of Philosophy
1509	Duke University
1510	Daniel Z. Buchman
1511	Bioethicist and Independent Scientist Centre for Addiction and Mental Health;
1512	Assistant Professor,
1513	Dalla Lana School of Public Health
1514	University of Toronto Isaac P. Campos
1515	Associate Professor of History
1516	University of Cincinnati
1517	Morgan Carpenter PhD Candidate in Bioethics
1518	Sydney Health Ethics
1519	The University of Sydney Gregg D. Caruso
1520	Professor of Philosophy
1520	SUNY Corning;
1521	Co-Director, Justice Without Retribution Network,
	School of Law
1523	University of Aberdeen
1524	Gabriel J. Chin Edward L. Barrett Jr. Chair and
1525	Martin Luther King Jr. Professor of Law
1526	School of Law
1527	University of California, Davis Nick Cowen
1528	Senior Lecturer in Criminology
1529	University of Lincoln
1530	John Danaher Senior Lecturer in Law
1531	National University of Ireland - Galway
1532	Juan Del Toro
1532	Postdoctoral Research Scientist University of Pittsburgh
1535	(Continued)
1535	(commuta)
1000	

Steven B. Duke	1536
Professor Emeritus of Law	1537
Yale Law School	
Ajua Duker	1538
Department of Psychology Yale University	1539
Jaime Anne Earnest	1540
Assistant Professor	1541
Center for Global Health Engagement	
Uniformed Services University	1542
of the Health Sciences	1543
(Personal Capacity)** Allan Arturo Gonzalez Estrada	1544
Head of Philosophy Department	1545
Universidad Nacional de Costa Rica	1546
Jessica Flanigan	
Richard L. Morrill Chair in	1547
Ethics and Democratic Values University of Richmond	1548
Nazgol Ghandnoosh	1549
Ph.D., Senior Research Analyst	1550
The Sentencing Project	1551
(Personal Capacity)**	
Phillip Atiba Goff Professor of African American Studies	1552
and Psychology	1553
Yale University	1554
Maji Hailemariam	1555
Assistant Professor	1556
College of Human Medicine Michigan State University	
Helena Hansen	1557
Associate Professor	1558
Departments of Anthropology and Psychia	atry 1559
New York University	1560
Michael Huemer Professor of Philosophy	1561
University of Colorado – Boulder	
Crista Johnson-Agbakwu	1562
Founder & Director,	1563
Refugee Women's Health Clinic	1564
Valleywise Health; Research Associate Professor	1565
School of Social Work;	1566
Director, Office of Refugee Health	15/7
Southwest Interdisciplinary Research Center	
Arizona State University Josephine Johnston	1568
Director of Research;	1569
Research Scholar	1570
The Hastings Center	1571
Sam Kamin	
Chauncey G. Wilson Memorial Research Chair and Professor	1572
University of Denver, Sturm College of La	w 1573
Julia Kolak	1574
Interim Clinical Director of Bioethics	1575
City College of New York	1576
Kojo Koram Lecturer in Law	
Birkbeck School of Law	1577
University of London	1578
Stephen R. Latham	1579
Director, Yale Interdisciplinary	1580
Center for Bioethics Yale University	1581
Jonathan Leighton	
Executive Director,	1582
Organisation for the Prevention of	1583
Intense Suffering	1584
Alexander Isaiah Darby Lester Director of Education,	1585
The Black Scranton Project	1586
	(Continued) 1580
	1507
	1588

Neil Levy	Walter Sinnott-Armstrong
Professor of Philosophy	Chauncey Stillman Professor of Practical Ethics
Macquarie University;	Duke University
Senior Research Fellow,	Jordan Sloshower Lecturer in Psychiatry
Uehiro Centre for Practical Ethics, University of Oxford	Yale University School of Medicine
Mona Lynch	Eric E. Sterling
Professor of Criminology, Law & Society	Executive Director
University of California, Irvine	Criminal Justice Policy Foundation
Moya Mapps	Aksel Braanen Sterri
Department of Philosophy	Ph.D. Fellow in Philosophy University of Oslo
Yale University	Walter Veit
Jonathan Ian Meddings Senior Policy Analyst	School of History &
Thorne Harbour Health	Philosophy of Science
Shaun Miller	The University of Sydney
Visiting Assistant Professor	Elliot Watts
Dalhousie University	Lawyer and Community Advocate Atlanta, Georgia
Jeffrey Miron	Peter West-Oram
Senior Lecturer in Economics Harvard University	Lecturer in Bioethics
Ole Martin Moen	Brighton and Sussex Medical School
Professor of Ethics in the Health Sciences	University of Sussex
Oslo Metropolitan University	Carl L. Hart *
Joshua Teperowski Monrad	Ziff Professor in Psychology (in Psychiatry)
MSc Candidate	Columbia University
Faculty of Public Health and Policy, London School of Hygiene and	*Brian D. Earp and Jonathan Lewis share first authorship. The senior
Tropical Medicine;	author is Carl L. Hart. All other authors are listed alphabetically. **Authors writing in personal capacity have listed affiliations for identifi-
Department of Health Policy,	cation; however, they should not be interpreted as speaking in any way
London School of Economics and	on behalf of their respective institutions or governmental organizations.
Political Science	
Ivars Neiders	
Assistant Professor Rīga Stradiņš University	
Niels Nijsingh	
Postdoctoral researcher in Public Health Ethics	
Ludwig Maximilian University, Munich	
Nathan Nobis	
Associate Professor of Philosophy	
Morehouse College Sven Nyholm	
Assistant Professor of Philosophical Ethics	
Utrecht University	
Keisha S. Ray	
Assistant Professor	
McGovern Center for Humanities & Ethics	
University of Texas Health Science Center at Houston Carolyn Roberts	
Assistant Professor	
History of Science & History of Medicine;	
African American Studies	
Yale University	
Daniel Rodger	
Senior Lecturer	
School of Health and Social Care London South Bank University	
Michael L. Rosino	
Assistant Professor of Sociology	
Molloy College	
Julian Savulescu	
Uehiro Chair in Practical Ethics	
University of Oxford Nneka Sederstrom	
Director of Clinical Ethics	
Children's Minnesota	
Arianne Shahvisi	
Senior Lecturer in Ethics	
Brighton and Sussex Medical School	
Peter Singer	
Ira W. DeCamp Professor of Bioethics University Center for Human Values	
Princeton University	
(Continued)	
(Continued)	